| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Biotin-4-aminophenol does not target a specific protein or enzyme itself. Instead, it serves as a substrate for peroxidases (such as horseradish peroxidase or APEX2) in proximity labeling applications. The compound generates free radicals upon oxidation by peroxidases, which then conjugate to tyrosine residues on nearby proteins. The biotin moiety enables the subsequent purification or detection of labeled proteins using streptavidin-based methods.
|
|---|---|
| ln Vitro |
The in vitro activity of Biotin-4-aminophenol is its function as a biotin-phenol analog for proximity labeling. The compound generates free radicals and conjugates to tyrosine residues in proteins more efficiently and selectively than previously reported BP1. In the presence of a peroxidase enzyme (such as HRP or APEX2) and hydrogen peroxide, Biotin-4-aminophenol is oxidized to form a reactive radical that covalently labels tyrosine residues on nearby proteins. The biotin tag allows for the isolation and identification of labeled proteins using streptavidin-based methods.
|
| ln Vivo |
Biotin-4-aminophenol is not used as a therapeutic agent. Its in vivo utility is limited to research applications involving proximity labeling for the identification of protein-protein interactions and protein localization. The compound is not intended for systemic therapeutic use.
|
| Enzyme Assay |
In vitro proximity labeling assays for Biotin-4-aminophenol involve incubating the compound with peroxidase enzymes (such as HRP or APEX2) and hydrogen peroxide in the presence of the protein sample. The peroxidase oxidizes Biotin-4-aminophenol to generate reactive radicals that conjugate to tyrosine residues on nearby proteins. The biotinylated proteins can be isolated using streptavidin beads and identified by mass spectrometry or Western blot.
|
| Cell Assay |
For in vitro cellular experiments, cells expressing a peroxidase-tagged protein of interest are incubated with Biotin-4-aminophenol. The peroxidase oxidizes the compound to generate radicals that label proteins in close proximity to the peroxidase. After labeling, cells are lysed and biotinylated proteins are isolated using streptavidin beads for identification by mass spectrometry. This method enables the mapping of protein-protein interaction networks and protein subcellular localization.
|
| Animal Protocol |
In vivo animal experiments with Biotin-4-aminophenol are not typically performed, as the compound is primarily used as a research tool for in vitro and cell-based proximity labeling.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Biotin-4-aminophenol have not been characterized, as the compound is a research-use proximity labeling reagent rather than a drug candidate. The compound has a molecular weight of 335.42 g/mol and should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
Biotin-4-aminophenol is intended for research use only and not for human therapeutic or diagnostic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| References | |
| Additional Infomation |
Biotin-4-aminophenol (BP) (CAS#: 901770-40-9) is a selective and potent biotin-phenol analog that generates free radicals and conjugates to tyrosine residues in proteins. It is used for proximity labeling applications and has no clinical or therapeutic applications.
|
| Molecular Formula |
C16H21N3O3S
|
|---|---|
| Molecular Weight |
335.42124247551
|
| Exact Mass |
335.13
|
| CAS # |
901770-40-9
|
| PubChem CID |
52905240
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
440
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C([C@@H]1SC[C@@H]2NC(N[C@H]12)=O)CCCC(=O)NC1C=CC(O)=CC=1
|
| InChi Key |
YDEOZJVNXVKRLR-YDHLFZDLSA-N
|
| InChi Code |
InChI=1S/C16H21N3O3S/c20-11-7-5-10(6-8-11)17-14(21)4-2-1-3-13-15-12(9-23-13)18-16(22)19-15/h5-8,12-13,15,20H,1-4,9H2,(H,17,21)(H2,18,19,22)/t12-,13-,15-/m0/s1
|
| Chemical Name |
5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-(4-hydroxyphenyl)pentanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (298.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9813 mL | 14.9067 mL | 29.8134 mL | |
| 5 mM | 0.5963 mL | 2.9813 mL | 5.9627 mL | |
| 10 mM | 0.2981 mL | 1.4907 mL | 2.9813 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
